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Abstract
Background: Activation of the signal transducer and activator of transcription 3 (STAT3) within antigen presenting cells
(APCs) is linked to abnormal APCs differentiation and function. We have previously shown that STAT3 is activated within
APC by a novel contact-dependent mechanism, which plays a key role in mediating the immunomodulatory effects of
hMSC. In order to better understand the underlying mechanisms that control APC maturation in a contact dependent
manner, we extended our observation to tumor cells. Tumors were shown to secrete a variety of tumor-derived factors that
activate STAT3 within infiltrating APCs. We now tested whether tumor cells can activate STAT3 within APC using the
contact-dependent mechanism, in addition to soluble factors, and compared these two STAT3 activating pathways.
Principal Findings: We demonstrate that in addition to tumor-derived secreted factors tumor cells activate STAT3 by a
mechanism that is based on cell-cell interaction. We further demonstrate that these two STAT3 activating mechanisms differ
in their JAK usage and their susceptibility to JSI-124 inhibition thereby representing two distinct pathways. Significantly,
although both pathways activate STAT3, they modulate DCs maturation in a different manner that results in disparate
phenotypic outcomes. Whereas the soluble-dependent pathway results in an immature phenotype, the contact-dependent
pathway results in an apparently mature phenotype. Albeit their mature-like phenotype these latter cells express the
tolerogenic markers ILT3 and ILT4 and possess T cell inhibitory activity.
Significance: This data suggests that, in at least certain cellular microenvironments, cell:cell interactions represent a novel
way to activate STAT3 signaling, uncouple APC activation events and consequently regulate immunity and tolerance.
Significantly, we have now demonstrated that this contact-dependent signaling pathway differs from that mediated by
soluble factors and cytokines, inducing disparate phenotypic outcome, suggesting these two mechanisms have different
and possibly complementary biological functions.
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Introduction
Antigen-presenting cells (APCs), and specifically dendritic cells
(DCs), are the most potent inducers of the immune response. DCs in
the periphery capture and process antigens in their immature state
followed by a maturation process in response to a spectrum of stimuli,
allowing them to induce both innate and adaptive responses[1]. Only
upon receiving maturation signals, DCs migrate to lymphoid organs,
secrete cytokines and express co-stimulatory molecules that are
required for lymphocyte activation [1]. In recent years, however,
there is growing evidence suggesting that DCs not only initiate T cell
responses but are also involved in silencing T cell immune responses.
These functions of DCs are thought to be mainly dependent on their
activation and differentiation state. For example, terminally differen-
tiated mature DCs can efficiently induce the development of effector
T cells, whereas immature DCs or partially matured DCs are
involved in maintenance of peripheral tolerance. Hence, APCs and
specifically DCs orchestrate a range of immune responses including
induction and suppression of T cell activation [1,2].
Regulation of DCs maturation occurs through the function of Janus
activated kinase (JAK)/signal transducer and activator of transcription
(STAT) signaling pathway [3]. The JAK family of tyrosine kinases and
STAT are important components of diverse signal transduction
pathways that are actively involved in cellular survival, proliferation,
differentiation and apoptosis. Four members of the Jak family have
been identified in mammalian cells, Jak1, Jak2, Jak3 and Tyk2 [4].
Cytokine receptor-ligand binding induces receptor oligomerization
and phophorylation, followed by Jak activation. Activated Jaks
phosphorylate receptors on target tyrosine residues, generating
docking sites for STATs, which are subsequently recruited and
phosphorylated by activated Jaks. Dimerized STATs then translocate
to the nucleus, where they modulate expression of target genes [5].
One of these proteins STAT3, has been implicated as a negative
regulator of the immune response [6]. Mice devoid of the STAT3
gene in macrophages and neutrophils have enhanced inflammatory
activity, leading to the development of chronic colitis [6].
STAT3 has been recently proposed as an important molecule
that mediates tumor induced immunosupression. STAT3 is
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6846constitutively active in many tumor cells and was found to have an
important role in oncogenesis [7]. In addition STAT3 was found
to have a profound role in regulating the immune responses in the
tumor micro-environment. In tumor cells, STAT3 activation has
been linked to both inhibition of pro-inflammatory cytokine
secretion and induction of anti-inflammatory cytokine secretion,
such as IL-10 and VEGF [8]. These latter anti-inflammatory
cytokines can, in turn, induce STAT3 activation within neighbor-
ing DCs, thereby influencing their functional maturation [8].
Collectively, tumor cells were shown to secrete soluble factors that
activate STAT3 and suppress DCs function.
An effective anti-tumor immune response requires the partic-
ipation of the host APCs, mostly DCs and macrophages [7].
Macrophages were shown to be recruited to the tumor site by
cytokines, chemokines and other tumor derived factors, and once
within the tumor environment they are skewed toward an anti-
inflammatory phenotype and thereby promote tumor growth [9].
DCs in the tumor microenvironment are usually found in an
immature state, characterized by an insufficient level of expression
of MHC class II complexes, co-stimulatory molecules such as
CD80 and CD86 and IL-12. These cells are not only poor
antigen-presenting cells, but could further induce immune
tolerance [10,11]. Tolerogenic DCs are generated in the absence
of inflammatory mediators, and recent studies have shown that
DCs can be further blocked from becoming effective antigen
presenting cells by tumor secreted factors that inhibit their
maturation [10,11].
We have previously described that human Mesenchymal Stem
Cells (hMSC) inhibit T cells indirectly by contact-dependent
induction of regulatory APCs (both monocytes and DCs) with T
cell suppressive properties [12]. Accordingly, when APCs came
into productive contact with hMSC, the secretion of pro-
inflammatory cytokines such as TNF-a and IL-12 were inhibited
while the anti-inflammatory cytokine IL-10 was induced. Under
these circumstances, IFN-c secretion and T- cell proliferation were
inhibited [12]. This contact-dependent induction of regulatory
APCs was dependent on the activation of STAT3 in these cells
and could be blocked with specific STAT3 inhibitors [13]. In the
present study, we demonstrated that tumor cells modulate APCs
function by using two parallel mechanisms for the activation of
STAT3; the first involving secretion of soluble cytokines as
previously described [8,14], and second involving a novel pathway
that is based on cell-cell interaction. While these two distinct
pathways activate STAT3 within APCs, they result in disparate
phenotypic outcomes. A contact-dependent mechanism may
provide a molecular explanation for how the surrounding
microenvironment influences APCs maturation in a focused and
unique way.
Results
Cancer cells inhibit TNF-a and IFN-c secretion while
inducing IL-10 production
Recent studies have suggested that tumor cells secrete tumor-
derived factors that induce STAT3 activity within neighboring
APCs, effecting their maturation and function [8]. Based upon our
previous insight into a contact-dependent effect of hMSC on APC
phenotype and function [12], along with the linking of this effect to
STAT3 activation [13], we now tested whether a similar contact-
dependent STAT3 activation is also induced in tumor cell-APC
interaction.
We started by co-culturing two different tumor cell lines (MCF-7
breast carcinoma; PC3 prostate carcinoma) with a mixture of
monocytes, T cells, and the superantigen SEB as activator. Both
tumor cell lines successfully inhibited IFN-c and TNF-a secretion
(Supporting data Fig. S1A) and promoted IL-10 secretion, with the
latter, primarily produced by the monocytes, as determined using
immunofluorescence and flow cytometry (Supporting data Fig. S1B).
Increased STAT3 activity in monocytes:tumor cells co-
cultures is dependent on both cell:cell contact and tumor
cells secreted factor(s)
We next assessed STAT3 activity in these co-cultures using
STAT3 transcription factor assay. As shown in figure 1, we
observed an increase in STAT3, but not STAT1 (not shown),
activity in tumor cells-monocyte co-cultures, as compared to each
cell type cultured individually. We further assessed the contribu-
tion of soluble and contact-dependent factors to the increase in
STAT3 activation in tumor cell-APC co-cultures. There is soluble
factor-dependence of STAT3 induced activity in the tumor cells-
monocyte co-cultures based on the increase in STAT3 activity in
monocytes when both PC3 and MCF-7 were replaced with their
conditioned media (Fig. 1 and 2A, lower panels), or when
monocytes and the tumor cells were on opposite sides of a
transwell membrane (not shown). However, the effect of
conditioned media was lower than the combined effect achieved
when the two cell types were co-cultured (Fig. 1 and 2A).
Therefore, to eliminate interference from tumor cytokines in the
co-cultures, tumor cell conditioned media was washed away just
prior to adding the monocytes. Under these conditions, we
observed significant increase in STAT3 activity after co-culturing
the cells compared to its activity in each cell type cultured
Figure 1. Increased STAT3 activity in co-cultures is dependent
on both cell:cell contact and secreted factor(s). Confluent
cultures of MCF-7 (2.5610
4/well) in a 24 well plate were incubated for
24 hours, then the cells were either left untreated or their conditioned
media was collected and replaced with fresh media (without
conditioned medium –c.m). Monocytes (2.5610
4 cells/well) were either
added to tumor cell’s cultures (both untreated and cells that received
fresh media-c.m.) or were incubated alone or with tumor cell’s
conditioned medium (c.m). After 2 hours, nuclear extracts were
prepared and tested for STAT3 activity using Non-Radioactive STAT3
Transcription Factor Assay. Comparable results were obtained in two
independent experiments.
doi:10.1371/journal.pone.0006846.g001
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contact may also contribute to STAT3 induction in addition to
soluble factors (Fig. 1). Furthermore, intracellular staining for
phosphorylated STAT3 revealed that this contact-dependent
increase resulted from STAT3 activity within the monocytes
(Fig. 2B).
Contact-dependent but not conditioned media or IL-10-
induced STAT3 activity and IL-10 production is sensitive
to JSI-124 inhibition
Cytokine receptors that lack an intrinsic tyrosine kinase activity
such as receptors for IL-10 and IL-6 rely on JAKs for initiating
their signaling cascade and STAT3 activation (reviewed in [4]).
Our previous data on hMSC:APC co-cultures [13] demonstrated
that STAT3 activity is abrogated upon treatment with JSI-124
(cucurbitacin), a small natural molecule that inhibits JAK2
signaling [15], suggesting that the contact dependent mechanism
may involve JAK2 signaling pathways. To further test this, we
have pretreated monocytes with JSI-124, for 1 hour prior to their
co-culturing with the tumor cells, or incubation with either IL-10
or tumor cell’s conditioned media. Pretreatment of the cells was
necessary in order to avoid JAK2/STAT3 inhibition in the tumor
cells while focusing on signaling events within the APC.
Pretreatment of monocytes with JSI-124, resulted in a significant
reduction in STAT3 activity (measured by both STAT3
transcription factor assay (Fig. 2A, upper panels) or phospho-
STAT3 intracellular immunostaining (Fig. 2B, left panel)) and in
IL-10 production by the monocytes (Fig. 3, lower panels) in tumor
cell:monocyte co-cultures. On the other hand, JSI-124 pre-
treatment had no effect on STAT3 activity (Fig. 2A, lower
panels), phospho-STAT3 immunostaining (Fig. 2B, right panel) or
IL-10 production (Fig. 3, upper panel) when monocytes were
incubated with MCF-7’s conditioned media. Likewise, JSI-124
had no effect on STAT3 activity (Fig. 4A) or phospho-STAT3
intracellular immunostaining (Fig. 4B) in IL-10-treated monocytes.
This activation of STAT3 as well as its sensitivity to JSI-124
Figure 2. Contact-dependent but not conditioned media-induced STAT3 activity is sensitive to JSI-124 inhibition. A. Monocytes were
either left untreated or treated with JSI-124 (10 mM) for 1 hour at 37uC, and then washed. Treated and untreated cells were then cultured alone or
were co-cultured with either MCF-7 or PC3 cells (upper panels) or with their conditioned media (lower panels). After 2 hours, nuclear extracts were
prepared and tested for STAT3 activity using Non-Radioactive STAT3 Transcription Factor Assay. Comparable results were obtained in four separate
experiments. B. Monocytes were either left untreated or treated with JSI-124 (10 mM) for 1 hour at 37uC, and then washed. JSI-124-treated and
untreated cells were then cultured alone or co-cultured together with tumor cells (MCF-7) or with tumor cell’s conditioned media. After 2 hours, cells
were harvested and phosphorylated-STAT3 was detected by intracellular immunostaining and flow cytometric analysis. The two cell types were
distinguished based on their forward and side scatter characteristics and phosphorylated STAT3 staining in monocyte population is shown. Dashed
line: isotype control; Filled grey area: monocytes alone; Thick grey line: monocytes that were either co-cultured with MCF-7 (left panel) or were
cultured in MCF-7 conditioned media (right panel); Black line: JSI-124-treated monocytes incubated with MCF-7 or their conditioned media, as above.
Comparable results were obtained in three independent experiments. C. Monocytes or DCs were either left untreated or treated with JSI-124 (as
indicated above), and then were co-cultured with MCF-7, for 2 hours. Untreated cells were obtained by mixing MCF-7 and either monocytes or DC
without incubation. Cell extracts were subjected to SDS-PAGE and immunoblotting of anti-phosphorylated STAT3 demonstrate induction of STAT3
and that JSI-124 treatment blocks contact-dependent STAT3 phosphorylation. Anti-STAT3 immunoblotting reveals relative amounts of protein in
each lane (lower panels).
doi:10.1371/journal.pone.0006846.g002
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STAT3 immunoblotting using both monocytes and DC co-
cultured with MCF-7 cells (Fig. 2C). Hence, using these specific
conditions (i.e. 1 h pre-treatment prior to stimulation) we could
discriminate between the soluble factor- and contact- dependent
STAT3 activating pathways. These results further support that in
tumor-APC interaction there is a contact-dependent activation of
STAT3 in APC, that unlike the parallel cytokine-mediated
pathway, is sensitive to JSI-124 inhibition (as is the case with
hMSC-APC co-cultures [13]).
Cell:cell contact but not conditioned media or IL-10
induce JAK2 phosphorylation
To further demonstrate the involvement of JAK2 in contact-
dependent STAT3 activation, we directly assessed JAK2 phosphor-
ylation in cell extracts from the various treatments using SDS-PAGE
and immunoblotting using anti-phosphotyrosine JAK2. A band
corresponding to phosphorylated JAK2 appeared only when
monocytes and tumor cells (MCF-7) were co-cultured together
(Fig. 5A) but not when either conditioned media or IL-10, were used
(Fig. 5B and C, respectively). As expected, this contact-dependent
JAK2 phosphorylation was significantly reduced upon pretreatment
of monocytes with JSI-124, paralleling that of phosphorylated
STAT3 (Fig. 5A). Significantly, while no phosphorylated JAK2 was
detected in either conditioned media or IL-10 treated monocytes,
phosphorylated STAT3 was readily detected and was insensitive to
JSI-124 treatment, (Fig. 5B and C and 6B). Of note, since only
monocytes were pre-treated with the inhibitor JSI-124, the reduced
level of phosphorylation of both JAK2 and STAT3 in the co-cultures
strongly suggests that these events originate in the monocytes.
phosphorylated-STAT3 co-immunoprecipitates with JAK2
upon MCF7:monocyte cell contact but not IL-10
treatment
Furthermore, we found that JAK2 and STAT3 are physically
associated and that the latter was tyrosine-phosphorylated after
Figure3.JSI-124inhibits IL-10 production induced by cell:cellcontactbutnotby tumor cell’sconditioned media. Monocytes were either
left untreated or treated with JSI-124 (10 mM) for 1 hour at 37uC, and then washed. JSI-124- treated and untreated cells were then cultured alone or co-
cultured together with tumor cells (PC3 or MCF-7, as indicated; lower panels) or with tumor cell’s conditioned media (upper panel). After 24 hours, cells
were harvested and IL-10 production was detected by intracellular immunostaining and flow cytometric analysis. Monocytes that were gated based on
their forward- andside-scatter characteristics are shown. Dashed line: Isotype control; Filled grey area: monocytes alone; Thick grey line: monocytes that
were either co-cultured with tumor cells (lower panels) or were cultured in MCF-7 conditioned media (upper panel); Black line: JSI-124-treated
monocytes incubated with tumor cells or their conditioned media, as above. Similar results were obtained in three independent experiments.
doi:10.1371/journal.pone.0006846.g003
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and monocytes were mixed together and were either lyzed
immediately or after 2 hours incubation, followed by JAK2
immuno-precipitation. Phosphorylated-STAT3 was detected in
JAK2 immunoprecipitates of MCF-7-monocyte co-cultures but
not in control cells (Fig. 6A) or in IL-10 stimulated monocytes
(Fig. 6B, left panel) although STAT3 phosphorylation is observed in
the latter (Fig. 6B, right panel). Taken together, these data indicate
that therearetwoseparate mechanismsfor the activation of STAT3
(soluble cytokines versus cell-cell contact) that differ in their usage of
JAKs and their susceptibility to inhibition by JSI-124.
DC exhibit a different phenotype upon cell:cell
interaction as compared to IL-10 treatment
Next we examined the effects of tumor secreted cytokines and
cell-cell contact on APCs maturation. To test this, DCs were co-
cultured with either MCF-7 cells or hMSC or alternatively treated
with IL-10 for 24 h followed by examination of maturation
markers by flow cytometry. Since MCF-7 cells induce STAT3
activation through both soluble factors and cell-cell contact,
hMSC were included in this experiment given that their induction
of STAT3 activity is solely dependent on cell-cell contact. As
shown in figure 7, hMSC co-culturing had only a slight and
statistically insignificant effect on the levels of HLA-DR and CD86
expression, while the levels of CD80 and CCR7 expression were
significantly elevated (P=0.007 and P=0.003, respectively)
compared to DCs single cultures. In contrast to cell-cell
interaction, HLA-DR and CD86 levels were significantly reduced
(P=0.007 and P,0.001, respectively) by IL-10 treatment, whereas
CD80 and CCR7 expression levels remained low (Fig. 7A). These
results were quantified as shown in figure 7B and demonstrate a
significant change in the pattern of maturation markers expression
between IL-10 treated DCs (soluble) and co-cultures of DCs and
hMSC (cell-cell contact), with the relative expression levels of
CD86, HLA-DR, CD80 and CCR7 significantly differing between
the two treatments. As expected, DC-MCF-7 co-cultures resulted
in an intermediate phenotype between that observed in DC-
hMSC co-cultures or in DCs treated with IL-10. This is consistent
with the findings that MCF-7 cells can induce both soluble- and
contact-dependent pathways in parallel. These findings represent a
unique developmental stage for DCs upon cell-cell interaction that
differs from the immature phenotype induced by IL-10.
Dendritic cells and monocytes express the inhibitory
receptors ILT3 and ILT4 upon interaction with MCF-7
cells, hMSC or IL-10
Immunoglobulin like transcript (ILT) are receptors structurally
and functionally related to killer-cell inhibitory receptors (KIRs),
containing long cytoplasmic tails containing immunoreceptor
tyrosine based inhibitory motifs (ITIMs) that inhibit cell activation,
and they have been shown to be involved in immune regulation.
Specifically, ILT3 and ILT4 expression is limited to monocytes,
macrophages and DCs. Expression of ILT3 and ILT4 on DC has
been associated with a tolerogenic phenotype which was shown to
be crucial to the tolerogenic capacity acquired by DCs [16,17].
Interestingly, despite the marked differences in the overall
phenotype between the contact- and soluble factor-dependent
mechanisms the levels of expression of these two markers for
tolerogenic APCs, ILT3 and ILT4 were upregulated in both DCs
and monocytes co-cultured with hMSC or MCF-7 as well as when
they were treated with IL-10 (Fig. 7C).
hMSC:monocytes co-culture actively inhibit T-cell
activation
Our previous results examining the immunomodulary effect of
hMSC suggest that the cell-contact mechanism conferred
immunoregulatory properties for APCs. Specifically, hMSC
inhibited T-cell activation only upon addition of APCs (DC or
monocytes) to the co-culture. The immunoregulatory properties
acquired by these APCs upon contact included induction of IL-10
secretion together with reduction in TNF-a and IL-12 secretion by
the APCs and inhibition of IFN-c secretion and proliferation of T-
cells [12]. In order to determine whether the contact-dependent
mechanism converts the APCs into what is effectively a ‘‘deletional
or inhibitory APC’’ with active immunoregulatory properties, as
opposed to simply being activation incompetent, we examined the
ability of these cell-contact conditioned APC to actively suppress T
cell activation. In these experiments T cells were activated with
anti-CD3 coated beads and soluble anti-CD28 that can stimulate
T cells in the absence of any APCs and placed in the upper
Figure 4. IL-10 induced STAT3 activity is insensitive to JSI-124 inhibition. JSI-124 treated and untreated monocytes (as described in figure 3)
were cultured with or without IL-10 (10 ng/ml). After 2 hours, cells were harvested and either lysed and their nuclear extracts were tested for STAT3
activity using Non-Radioactive STAT3 Transcription Factor Assay (left panel) or phosphorylated STAT3 was detected by intracellular immunostaining
and flow cytometric analysis (right panel). Dashed line: Isotype control; Filled grey line: monocytes alone; Thick grey line: IL-10 stimulated monocytes;
Black line: IL-10 stimulated JSI-124 pretreated monocytes. Comparable results were obtained in three independent experiments.
doi:10.1371/journal.pone.0006846.g004
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were placed in the bottom chamber (to avoid contact between the
monocytes and T cells that can contribute to T cell activation) and
their effect on bead-stimulated T cell activation was determined by
IFN-c secretion. Here again hMSC were used and not cancer cells
in-order to determine the exclusive contribution of the contact
depended effect and to avoid the additional effect of soluble factor
secreted by the cancer cells over the 72 h period. Inhibition of
IFN-c secretion was observed only when hMSC and monocyte
were co-cultured in the lower chamber but not when each cell type
was cultured alone (Supporting data Fig. S2). This data support
our previous reports that upon cell-cell contact the APCs are
converted into functionally regulatory cells via STAT3 activation
and that this T cell inhibitory activity is partially mediated by a
soluble factor secreted only upon cell-cell interaction [12,13].
Discussion
Cancer cells utilize different mechanisms to evade immune
surveillance. One way is by influencing APCs within the tumor
bed rendering them tolerogenic. Recent studies have shown that
tumors secrete factors that inhibit DCs maturation through
activation of STAT3 in DCs [7]. Here we show that in addition
to releasing soluble factors, tumor cells, physically interact with
APCs, consequently inducing the activation of STAT3. This
induction results in APCs with a distinct phenotype, which are
capable of inhibiting T-cell activation. Thus, tumor cells have at
least two pathways by which they can alter APCs maturation and
function. The first, described previously, is mediated by tumor-
derived factors such as VEGF and IL-10, that promote the
generation of immature DCs that lack the T cell stimulatory
activity characteristic of mature DCs [7]. The second pathway,
demonstrated in this study, is a novel cell contact induced and
JAK2-dependent pathway that generates tolerogenic DCs with a
distinct altered-mature phenotype that actively suppress T-cell
activation. Hence, although the two pathways converge on
activation of STAT3 they subsequently diverge in their down-
stream effect on APC phenotype.
In the current study, by simply washing the cells just prior to
adding the APC we eliminated the contribution of tumor-secreted
factors, thereby revealing the contact-dependent activation of
STAT3. Second, we found that the cell contact-dependent
pathway is sensitive to treatment with the JAK2 inhibitor JSI-
124, distinguishing it from the soluble factor pathway. Third,
phosphorylation of JAK2 and physical interactions between JAK2
and phosphorylated-STAT3 are contact dependent. These
Figure 5. Cell:cell contact but not conditioned media or IL-10
induce JAK2 phosphorylation. Monocytes were either left untreat-
ed or treated with JSI-124 (as indicated above), and then were treated
with either IL-10 (10 ng/ml), MCF-7’s conditioned media or were co-
cultured with MCF-7, for 2 hours. Untreated cells in the case of co-
cultures were obtained by mixing MCF-7 and monocytes without
incubation. Cell extracts were subjected to SDS-PAGE and anti-
phosphorylated JAK2 immunoblotting (upper panels). Immunoblotting
of anti-phosphorylated STAT3 demonstrates induction of STAT3
activation by all treatments regardless of JAK2 phosphorylation (middle
panels) and that JSI-124 treatment selectively blocks contact- and JAK2-
dependent STAT3 phosphorylation. Anti-STAT3 immunoblotting reveals
relative amounts of protein in each lane (lower panels). Similar results
were obtained in three independent experiments.
doi:10.1371/journal.pone.0006846.g005
Figure 6. phosphorylated-STAT3 co-immunoprecipitates with
JAK2 upon MCF7:monocyte cell contact but not IL-10 treat-
ment. A: Monocytes were either co-cultured with MCF-7, for 2 hours or
mixed with MCF-7 without incubation as a control, and then lysed. B:
monocytes were either left untreated or were treated with IL-10 (10 ng/
ml) for 2 hours, and then lysed. Cell extracts were subjected to
immunoprecipitation by anti-JAK2 antibodies and the precipitates were
separated on SDS-PAGE. Anti-phosphorylated STAT3 immunoblotting
demonstrates that phosphorylated-STAT3 associates with JAK2 upon
contact-dependent activation but not IL-10 treatment (upper panels).
Anti-JAK2 immunoblotting reveals relative amounts of protein in each
lane (lower panels). In B (right panels), total lysates are shown to
demonstrate STAT3 is phosphorylated upon IL-10 treatment although
did not co-precipitate with JAK2, and phosphorylation of the latter is
not induced by IL-10. Similar results were obtained in three
experiments.
doi:10.1371/journal.pone.0006846.g006
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either incubated alone, co-cultured with hMSC (top panel) or MCF-7 (middle panel), or were treated with IL-10 (10 ng/ml; lower panel). After 24 hours,
the cells were collected and the levels of HLA-DR, CD80, CD86 and CCR7 surface expression on DCs were determined by immunofluorescence and flow
cytometry.Blackline:isotype control; blue line DCsalone;Redline:DCsco-culturedwithhMSC;Greenline:DCsco-culturedwithMCF-7; Orange line:DCs
treated with IL-10 one representative experiment is shown (A). Mean fluorescent intensity (MFI) results as in A from 5 experiments were normalized and
are presented as relative to the level of expression by DCs cultured alone (B). Either DCs or monocytes treated as above were further tested for surface
expression of ILT3 and ILT4 by immunofluorescence and flow cytometry. Black line: isotype control; blue line: DCs or monocyes as indicated, alone; Red
line: co-culture with hMSC; Green line: co-culture with MCF-7; Orange line: incubation with IL-10 (C).
doi:10.1371/journal.pone.0006846.g007
Contact Induced Regulatory DC
PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6846findings suggest that these are two distinct mechanisms for STAT3
activation that differ in their signaling pathways.
Besides cytokines and their receptors, STATs can be activated
by other means, for example by growth factor receptors, such as
EGF, PDGF, and CSF-1, which all possess an intrinsic tyrosine
kinase activity [18], as well as by non-receptor tyrosine kinases
such as Src and Abl, and through serpentine receptors such as
those for angiotensin II, serotonin, and a-melatonin stimulating
hormone [19,4]. In addition, we have previously demonstrated,
the induction of STAT3 signaling in APCs upon cell contact
with hMSC, suggesting a new pathway for activating STAT3 in
APCs. In a different setting, contact-dependent activation of
STAT3 has been also demonstrated in normal and cancer breast
cells. A study by Vultur et. al. showed a dramatic increase in
STAT3 phosphorylation and consequently STAT3 activity with
cell density in normal cells. This confluence-dependent activa-
tion was eliminated if cell-cell interactions were interrupted
through calcium chelation [20]. The contact dependent
activation of STAT3 described by Vulture et.al may be due to
a mechanism similar to the one we describe here for a
heterologous interaction between APCs and their cellular
environment, suggesting that a contact dependent activation of
STAT3 may be a more general mechanism. Taken together, one
can speculate the existence of yet unknown surface molecules
participating in intercellular contact that are dependent on
JAK2 for their activity. The finding of such surface molecules
requires further investigation.
D C sp l a yak e yr o l ei nt h ei n i t iation and regulation of the
immune response, and their ability to initiate immune reaction
or induce tolerance is strictly dependent on their maturation
s t a t ea n dp h e n o t y p e .W h i l ei mmature DCs can induce T-cell
anergy, mature DCs activate T cells and induce immunity.
Nonetheless, it has also been reported that DCs may exist in a
semi-mature state in which they are capable of actively
inhibiting T cell activity, generating regulatory T-cell and
promoting tolerance [2]. In this report, we found that contact-
dependent activation of STAT3 induced the generation of
functionally regulatory DCs with a seemingly semi-mature or
aberrantly-mature phenotype, whereas IL-10 treatment resulted
in DCs that express low levels of costimulatory molecules and
HLA-DR, consistent with an immature phenotype. This data is
in agreement with previous studies that described DCs with
regulatory function that varied in their maturation phenotypes
[21,22,23]. Among these are two reports describing the
generation of regulatory DCs originating from mature cells
rather than from immature cells [7,24]. Therefore, it seems that
the hallmark of regulatory DCs is their ability to functionally
inhibit lymphocyte activation rather than their specific pheno-
type and maturation stage. In agreement with this notion, we
further demonstrated that despite the different phenotypic
outcomes, both IL-10 and cell-cell contact induced the
expression of the inhibitory receptors Immunoglobulin like
transcript (ILT) 3 and 4, which are characteristic of regulatory
DCs, and play a role in their T cell inhibitory activity. Hence,
ILT3 and ILT4 expression may account for the inhibitory
activity of these cells regardless of their overall phenotype.
In response to an inflammatory stimuli, DCs up-regulate the
expression of the chemokine receptor, CCR7 and migrate from
peripheral tissues to secondary lymphoid organs [25]. While this
event is usually linked to the process of DC’s maturation, a
previous study has demonstrated that after exposure to apoptotic
cells DCs up-regulated CCR7 expression despite the absence of
maturation properties [26]. Hence, the authors further speculated
that CCR7-expressing immature DCs that ingested apoptotic
material may migrate to peripheral lymph nodes, in order to
maintain tolerance [26]. In our study we show that contact-
dependent induced regulatory DCs up-regulate the expression of
CCR7 thereby enabling these DCs to migrate to lymphoid tissues
where they may induce tolerance. Notably, CCR7 is induced only
by the contact-dependent mechanism and not by soluble factors,
further emphasizing the potential importance of the contact-
dependent mechanism in tolerance induction, such as in the case
of tumors.
In the context of cancer, modulating APCs in a contact-
dependent manner may be of special significance in the pre-
malignant stage. Physiologically, tumors arise sporadically and
between the initiating oncogenic event and tumor progression
there might be a long pre-malignant stage. However, data
concerning the interaction between tumor cells and the immune
system was obtained from models in which the host was exposed to
a large number of cells at a single time point. A recent study by
Willimsky et.al. [27], has addressed the question of immunoge-
nicity of pre-malignant lesions, by using a transgenic mouse model
for sporadic cancer. The authors of this study concluded that
tolerance occurs already at the pre-malignant stage, before tumor
progression. Specifically, they showed the accumulation of
immature myeloid cells at the pre-malignant stage, and suggest
they play a role in creating T-cell unresponsiveness. Given our
results, one may speculate that at the pre-malignant stage physical
interactions between resident APCs and tumor cells that activate
STAT3 play a significant role in tumor escape, long before tumors
are visible and large enough to secrete significant amounts of
APCs-modulating factors.
Materials and Methods
Cells
Cells were purified from the venous blood of healthy donors.
Either, CD4
+ T cells or CD14
+ cells were isolated by negative
selection using the RosetteSep
TM enrichment cocktail (StemCell
Technologies, Vancouver, Canada). hMSC were obtained from
discarded bone tissues from patients undergoing total hip
replacement surgeries, under approval of Hadassah Medical
Center Helsinki Ethics Committee following an informed consent.
The hMSC were separated from other bone-marrow residing cells
by plastic adherence, and were then grown under tissue culture
conditions, as previously described [13]. The cells were main-
tained in a low-glucose DMEM medium supplemented with 10%
heat-inactivated fetal calf serum, 2 mM glutamine, and penicillin/
streptomycin (Biological Industries, Beit-Haemek, Israel). For DC
generation, CD14
+ cells were plated in RPMI 1640 (Biological
Industries) containing 1% autologous plasma, 0.1 mg/ml IL-4 and
0.1 mg/ml GM-CSF (PeproTech, Rocky Hill, NJ). Every 2 days
0.3 ml were removed and 0.5 ml media containing plasma and
cytokines were added. By day 7, .90% of the cells were CD14
-
and CD11c
+ immature DCs. For JAK blockade freshly isolated
CD14
+ cells or DC were pre-incubated with JAK2 inhibitors, JSI-
124 (cucurbitacin I; Calbiochem,). Human breast adenocarcinoma
(MCF7) and human prostate adenocarcinoma (PC3), cell lines
were obtained from the American Type Culture Collection
(ATCC). MCF7 cells were cultured in DMEM with 10% heat-
inactivated fetal calf serum, 2 mM glutamine, and penicillin/
streptomycin (Biological Industries, Beit-Haemek, Israel) at 37uC
and 5% CO2. PC3 cells were cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium (Biological Industries, Beit-
Haemek, Israel) supplemented with 10% heat-inactivated fetal
calf serum (Biological Industries), 2 mM glutamine, and penicillin/
streptomycin, at 37uC and 5% CO2.
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Either tumor cells and APC (either monocytes or DCs) alone, or
the mixture of the two were incubated at 37uC. After 2 hours,
whole cell extracts were prepared using lysis buffer (0.5% Nonidet
P-40, 50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM PMSF,
1 mM sodium orthovanadate, 10 mg/ml leupeptin, and 10 mg/ml
aprotinin) for 20–30 min on ice. Lysates were separated by
electrophoresis on 10% SDS-PAGE gels and then transferred to
PVDF membranes (Bio-Rad, Hercules, CA). The blots were
probed with anti-phosphorylated STAT3 mAb (Tyr705; Cell
Signaling, Danvers, MA) or anti-phosphorylated Jak2 mAb
(Tyr1007/1008; Cell Signaling, Danvers, MA) processed with
ECL plus Western Blotting detection system (Amersham-
Pharmacia Biotech), and exposed to Chemiluminescence BioMax
Light Film (Kodak-Industries, Cedex, France). Following stripping
the membranes were re-probed with anti-STAT3 mAb (Santa-
Cruz Biotechnology, Santa-Cruz, CA) or anti-JAK2 Rabbit mAb
(Cell Signaling, Danvers, MA).
STAT3 transcription factor activity assay
Tumor cells and APC (either monocytes or DC) were incubated
either alone or co-cultured together for 2 hours and then nuclear
extracts were prepared using Nuclear Extraction kit (Chemicon
International, Temecula, CA). The lysates were then used to
determine the specific binding of STAT3 to their respective targets
using a STAT3 transcription factor assay kit (Chemicon
International,) and the results were confirmed with the Human
Active STAT3 DuoSet IC kit (R&D systems, Minneapolis, MN).
Specificity was determined using non-specific oligomer as well by
competing the binding with non-biotinylated oligomer supplied in
the kit.
Cytokine production
Cultures containing 5610
4 CD4
+ T cells and 5610
4 monocytes
in the presence of the superantigen SEB (1 ng/ml; Sigma, St.
Louis, MO), and in the absence or presence of tumor cells (5610
4),
were plated in individual wells of flat-bottom 96-well plates
(Corning, Corning, NY). Cells were stimulated for 72 hours and
conditioned media were collected. IFN-c levels in the conditioned
media were assayed by ELISA (R&D Systems). IL-10 secretion
was determined in the conditioned media of either monocytes,
tumor alone or co-culture of the two using commercial ELISA
(R&D Systems).
Intracellular staining and Flow cytometry
Monocytes and tumor cells were cultured alone or mixed
together for 24 hours, with the addition of 2 mM monensin for the
last 5 hours of stimulation. Then the cells were harvested, washed
twice in PBS, fixed in 4% paraformaldehyde for 30 minutes,
washed twice in PBS 1% FCS, resuspended in 0.1% saponin, 1%
FCS/PBS, and stained using PE-conjugated anti-cytokine IL-10
(Serotec, Oxford, UK) or anti-phosphorylated STAT3 antibodies
(Santa-Cruz Biotechnology), for 30 minutes. Cells were washed
twice in PBS, and the immunostained cells (1610
4 cells/sample)
were analyzed on a FACS Calibure flow cytometer (Becton
Dickinson, San Jose, CA) using the Cell Quest software.
Immunoprecipitation
For immunoprecipitations, whole cell lysates (prepared as
described above) were precleared for 1 h with protein A-sepharose
beads (Sigma-Aldrich St. Louis, MO, USA), and then incubated
with the anti-JAK2 Rabbit mAb (Cell Signaling) for at least 1 h
and then protein A-Sepharose beads were added and incubated
o.n with gentle rotation. Beads were then washed three times in
500 ml of lysis buffer. Samples were resuspended in reducing SDS
sample buffer, heated at 95uC for 5 min, and separated by SDS-
PAGE, and proteins were transferred to PVDF membrane (Bio-
Rad, Hercules, CA) for analysis by Western blotting.
APC phenotype
DCs were cultured for 24 hours in the absence or presence of
hMSCs, tumor cells or IL-10. CD86 (PharMingen, BD Biosci-
ences, Mississauga, ON. Canada), human leukocyte antigen-DR
(HLA-DR) (Serotec), CD80 (Biolegend San Diego, CA), CCR7
(BD Biosciences, Mississauga, ON. Canada), ILT3 (R&D Systems)
and ILT4 (R&D Systems) expression was measured by direct
immunofluorescence using conjugated antibodies, and the immu-
nostained cells were analyzed on a FACSCaliber flow cytometer
(Becton Dickinson, San Jose, CA) using CELLQuest software
(Becton Dickinson). The data were calculated as the mean
Fluorescence intensity.
APC function
CD4
+ T-cells were stimulated with anti-CD3 mAb (OKT3;
eBioscience San Diego, CA, USA) immobilized on protein A-
sepharose beads (Sigma-Aldrich) in combination with soluble anti-
CD28 mAb (0.5 mg/ml;R&D Systems) and placed in the upper
chamber of a transwell. Either monocytes, hMSC alone or in
combination were placed in the lower chamber. After 72 hr.
medium was collected and IFN-c levels in the conditioned media
were assayed by ELISA (R&D Systems).
Supporting Information
Figure S1 Cancer cells inhibit TNF-a and IFN-c secretion while
inducing IL-10 production. A: Monocytes were used to activate
autologuos CD4+ T cells (each 56104 cells per well) with SEB
(1 ng/ml) in the presence or absence of either MCF-7 (upper
panels) or PC3 (lower panels; 56104 cells), in triplicate wells of a
96 well dish. After 72 hours, conditioned media were collected and
the level of IFN-c and TNF-a were determined using ELISA. The
data represent the mean values of triplicate samples and standard
deviations. Data represents one of three experiments. B: Upper
panels: monocytes and PC3 were cultured alone or were co-
cultured together in triplicate wells of a 96 well dish. After
72 hours, conditioned media was collected and the level of IL-10
was determined using ELISA. The data represent the mean values
of triplicate samples and standard deviations. Lower panels:
Monocytes and either MCF-7 or PC3 were cultured alone or were
co-cultured together. After 24 hours, the cells were harvested and
IL-10 was detected by intracellular immunostaining and flow
cytometric analysis. Monocytes that were gated based on their
forward- and side-scatter characteristics are shown. Dashed line:
isotype control; Filled grey area: monocytes alone; Black line:
tumor cells:monocytes co-culture; Comparable results were
obtained in three separate experiments.
Found at: doi:10.1371/journal.pone.0006846.s001 (0.11 MB TIF)
Figure S2 hMSC conditioned monocytes actively inhibit T-cell
activation. T cells were activated with anti-CD3 coated beads and
soluble anti-CD28 and were placed in the upper chamber of a
transwell. Monocytes, hMSC or their co-culture were placed in the
bottom chamber. After 72 hours, conditioned media were
collected and the level of IFN-c was determined using ELISA.
The data represent the mean values of triplicate samples and
standard deviations. Data represents one of three experiments.
Found at: doi:10.1371/journal.pone.0006846.s002 (0.07 MB TIF)
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